Adding drinks with high fructose content to a diet that already includes high fat content can accelerate the chances of fatty liver disease, according to scientists at the University of Barcelona.
The "Nonalcoholic Steatohepatitis (NASH) Epidemiology Forecast to 2032" report has been added to ResearchAndMarkets.com's offering. The Nonalcoholic Steatohepatitis (NASH) epidemiology division provides
Primary endpoint (PDFF) was achieved in both Intention to Treat and Per Protocol PopulationsVANCOUVER, Wash. (BUSINESS WIRE) CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications,.
/PRNewswire/ Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that one.
Ipsen is paying €120 million up front to acquire global rights to elafibranor, a Genfit drug that fell short as a treatment for NASH, but is currently in Phase 3 testing in another liver disease, primary biliary cholangitis. Meanwhile, Genfit is adding an early-stage drug candidate to its own pipeline via a separate transaction.